You are here

  • Home
  • Archive
  • Volume 82, Issue 2
  • Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Article info

Article menu

This article has a correction. Please see:

Download PDFPDF
Rheumatoid arthritis
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Authors

  • Lea Hoisnard Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique - Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, Île-de-France, France Centre d’Investigation Clinique 1430, INSERM, Créteil, Ile-de-France, France EpiDermE Epidemiology in Dermatology and Evaluation of Therapeutics, EA7379, Paris ESt Créteil University UPEC, Créteil, France PubMed articlesGoogle scholar articles
  • Laura Pina Vegas Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique - Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, Île-de-France, France EpiDermE Epidemiology in Dermatology and Evaluation of Therapeutics, EA7379, Paris ESt Créteil University UPEC, Créteil, France Department of Rheumatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France PubMed articlesGoogle scholar articles
  • Rosemay Dray-Spira EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France PubMed articlesGoogle scholar articles
  • Alain Weill EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France PubMed articlesGoogle scholar articles
  • Mahmoud Zureik EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France PubMed articlesGoogle scholar articles
  • Emilie Sbidian Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique - Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, Île-de-France, France Centre d’Investigation Clinique 1430, INSERM, Créteil, Ile-de-France, France EpiDermE Epidemiology in Dermatology and Evaluation of Therapeutics, EA7379, Paris ESt Créteil University UPEC, Créteil, France EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France Department of Dermatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Lea Hoisnard, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique - Hôpitaux de Paris, Paris, Île-de-France, France; lea.hoisnard{at}aphp.fr
View Full Text

Citation

Hoisnard L, Pina Vegas L, Dray-Spira R, et al
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Annals of the Rheumatic Diseases 2023;82:182-188.

Publication history

  • Received May 20, 2022
  • Accepted August 25, 2022
  • First published October 5, 2022.
Online issue publication 
November 01, 2023

Article Versions

Copyright information

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.